Shin Dong-bin Makes First Visit to Lotte Biologics Songdo Plant 1... Reviews Global Order Strategies
Yoo-Yeol Shin and Other Executives Join the Visit
Strengthening On-Site Management for the New Bio Business
Production Preparations Near Completion
Accelerating Global Client Order Expansion
Shin Dong-bin, Chairman of Lotte Group, visited Lotte Biologics Songdo Campus Plant 1 to review the site’s production readiness and global order strategies, stepping up efforts to oversee the group’s new bio business.
Shin Dong-bin, Chairman of Lotte (first on the left), visited Lotte Biologics Songdo Campus Plant 1 in Yeonsu-gu, Incheon on the 3rd to engage in on-site management. Chairman Shin is seen touring the research facilities inside the plant and receiving explanations about the production process. Provided by Lotte Group
View original imageLotte Group announced on July 5 that Chairman Shin visited Lotte Biologics Songdo Campus Plant 1 in Yeonsu-gu, Incheon, on the 3rd. He toured the key production facilities and encouraged employees. After reviewing overseas operations of the group’s distribution and food affiliates in Vietnam in April, Chairman Shin continued his on-site management by visiting the group’s bio business, which is positioned as a future growth driver.
This visit took place immediately after Songdo Plant 1 completed major construction and received its occupancy permit, about two years after breaking ground. The site was also attended by James Park, Co-CEO of Lotte Biologics; Shin Yooyeol, Co-CEO of Lotte Biologics and Head of Future Growth at Lotte Holdings; and Oh Ilgeun, CEO of Lotte Engineering & Construction.
Chairman Shin personally inspected the main production processes at the facility and was briefed on the status of global client orders and future business strategies.
Chairman Shin emphasized, "Bio is a core industry group that will drive a new leap forward for the group," and asked, "Please do your utmost to ensure that all scheduled plans after completion proceed without any setbacks."
With this occupancy approval, Lotte Biologics has completed the installation of production equipment and the establishment of key systems, entering the full-scale stage of preparing for orders and commercial production. The company has established a "dual-site" operational system that links initial clinical and small-scale production at the Syracuse, U.S. plant with large-scale commercial production at the Songdo plant. Data-driven process technologies such as the Manufacturing Control System (MCS), digital twin, and computational fluid dynamics (CFD) simulation have also been applied.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lotte Biologics plans to conduct pilot operations and production system validation in the second half of the year and aims to obtain Good Manufacturing Practice (GMP) certification for pharmaceuticals within the year. This schedule is about six months ahead of the original plan, and the company intends to accelerate its expansion of the global Contract Development and Manufacturing Organization (CDMO) business.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.